Dickinson Andrew D

Dickinson Andrew D, chief financial officer of Gilead Sciences (GILD), has filed 59 Form 4 transactions, all in that single company. The pattern is one-sided: he has recorded zero open-market purchases and zero acquisitions of shares for cash. His total sales value across all filings is $37,214,787.83, with the most recent 12 trades all being sales or automatic tax-related withholdings. The recent activity shows a steady cadence of monthly open-market sales, each in the $313,000 to $468,000 range. On October 15, 2026, he sold shares worth $468,660. That followed a September 15 sale of $435,870 and an August 17 sale of $415,080. The sales have been consistent since late 2025, including a $313,075 sale on November 17, 2025, and a $366,000 sale on December 15, 2025. The largest single sale in the recent window was $463,290 on February 17, 2026. Interspersed with these sales are Form 4 codes that do not reflect discretionary selling. Several "F" codes show shares withheld to cover tax obligations, including a $3,553,630.56 withholding on February 3, 2026, and a $467,518.32 withholding on March 10, 2026. The "M" codes for option exercises on those same dates carry a value of zero, meaning the exercise price equaled the market price. Grant awards ("A" codes) also appear with zero value. The overall picture is a CFO who regularly sells GILD stock on the open market, but the non-sale codes are mechanical and compensation-related, not purchases.